Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06123338 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
A Phase 2 study of Esophageal Cancer and Gastric Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 10
- Study locations
NCT06123338 is a Phase 2 study of Esophageal Cancer and Gastric Adenocarcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT06123338, a Phase 2 study of Esophageal Cancer and Gastric Adenocarcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
Study Locations (10)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Massachusetts
- Massachusetts General Hospital (Data Collection Only) - Boston
Pennsylvania
- University of Pennsylvania (Data Collection Only) - Philadelphia
Texas
- MD Anderson Cancer Center (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06123338
The ClinicalTrials.gov registry entry for NCT06123338 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06123338 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06123338 about?
NCT06123338 is a clinical study titled "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer". The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
What is the current status of trial NCT06123338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2024-02-01. Estimated completion is 2027-11-30.
What conditions does trial NCT06123338 study?
This clinical trial studies the following conditions: Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation.
What interventions are being tested in trial NCT06123338?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT06123338?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06123338 being conducted?
This trial has 10 study locations across Massachusetts, New Jersey, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.